KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VivoSim Labs (VIVS) Cash & Equivalents (2016 - 2025)

VivoSim Labs (VIVS) has 16 years of Cash & Equivalents data on record, last reported at $4.3 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 269.34% year-over-year to $4.3 million; the TTM value through Dec 2025 reached $4.3 million, up 269.34%, while the annual FY2025 figure was $11.3 million, 289.93% up from the prior year.
  • Cash & Equivalents reached $4.3 million in Q4 2025 per VIVS's latest filing, down from $6.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $37.4 million in Q1 2021 and bottomed at $1.2 million in Q4 2024.
  • Average Cash & Equivalents over 5 years is $14.9 million, with a median of $11.0 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: plummeted 81.04% in 2024, then skyrocketed 289.93% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $30.3 million in 2021, then crashed by 33.28% to $20.2 million in 2022, then crashed by 73.78% to $5.3 million in 2023, then tumbled by 78.07% to $1.2 million in 2024, then skyrocketed by 269.34% to $4.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $4.3 million in Q4 2025, $6.7 million in Q3 2025, and $9.1 million in Q2 2025.